Eric N. Johnson
Papers
1
Total Citations
22
H-Index
1
About
Eric N. Johnson is a pharmaceutical researcher specializing in G protein-coupled receptor (GPCR) biology and high-throughput drug discovery technologies. His work sits at the critical intersection of biochemical assay development and therapeutic target identification, focusing particularly on orphan GPCRs — receptors whose natural ligands and functions remain poorly understood yet hold significant promise for drug development. Johnson's most recognized contribution involves the development of a miniaturized 1,536-well [³⁵S]GTPγS scintillation proximity assay (SPA), published in 2008, which enabled ultra-high-throughput screening of Gαi-coupled orphan GPCRs. This technical achievement represented a meaningful advance in drug discovery infrastructure, allowing researchers to screen vast compound libraries against previously intractable receptor targets with greater efficiency and reduced reagent consumption. The work has accumulated 22 citations, reflecting its specialized but meaningful impact within the GPCR pharmacology and drug screening communities. By engineering scalable binding assays for seven-transmembrane receptors — a superfamily implicated in conditions ranging from cardiovascular disease to neurological disorders — Johnson's research has helped lower barriers to identifying novel therapeutic candidates. His contributions are particularly valuable to early-stage drug discovery teams navigating the challenges of deorphanizing GPCRs with limited pharmacological tools.
Research Focus
Key Achievements
Top Papers
- 1